Interleukin-2 In An Alternative Dose (The Iliad Trial): Treatment Of Patients With Metastatic Renal Cell Carcinoma With Low Dose Proleukin
- Determine the overall response rate, complete and partial response rates, and duration
of response in patients with metastatic renal cell carcinoma treated with low-dose
- Determine the overall survival, one-year progression-free survival, and two-year
progression-free survival in patients treated with this regimen.
- Determine the incidence of adverse events in these patients.
OUTLINE: This is a multicenter study.
Patients receive low-dose interleukin-2 subcutaneously 5 days a week for 6 weeks. Courses
repeat every 9 weeks for at least 2 courses in the absence of disease progression or
Patients are followed every 3 months for 2 years.
PROJECTED ACCRUAL: A total of 464 patients will be accrued for this study.
Primary Purpose: Treatment
Cindy Connell, MD, PhD
University Hospitals Seidman Cancer Center
United States: Federal Government
|Ireland Cancer Center||Cleveland, Ohio 44106-5065|
|Northwestern Connecticut Oncology-Hematology Associates||Torrington, Connecticut 06790|